Capital is the easy part to commoditize. This is the part that isn't.
Every fund says it's a value-add partner. Here is specifically what that means at OceansGled, and specifically why our structure makes it credible rather than a slide in a pitch deck.
This page sits alongside — not instead of — our Value-Add page, which details the six concrete things we do for portfolio companies day to day. This page is the layer above that: why the fund is built the way it is, and why that structure is what makes the value-add real.
Six reasons the structure is credible.
Concentrated conviction, not spray and pray.
A twenty-five-company cap per fund, with a $10M minimum check, means every position gets real board-level attention rather than a line on a portfolio spreadsheet. We turn down more good companies than most funds our size because they don't clear the bar for genuine conviction, not because we've run out of capital.
See our approach to portfolio construction in Insights → Concentrated Conviction, Revisited.
We're on the ground, not flying in for diligence.
Six offices — Cheyenne, Mumbai, Hyderabad, Singapore, Abu Dhabi, and Chennai — aren't a marketing map. They're where our origination actually happens: local counsel relationships, regulatory fluency specific to each market, and founder networks built over years, not weeks before a term sheet.
See Insights → The Gulf's Healthcare Capital Pivot, India's CDMO Moment, and Africa's Healthcare Access Gap for how this plays out market by market.
The people advising you have actually built and exited healthcare companies.
Our operating and venture partner bench — former pharma R&D leaders, MedTech commercial executives, and healthcare system CIOs — engage on specific inflection points: pivotal trial design, regulatory strategy, cross-border commercialization, executive search. This isn't a rolodex; it's structured, compensated engagement tied to the moments that actually determine whether a company clears its next milestone.
Learn more → Collaborate: Operating & Venture Partners.
Diligence pressure-tested by people who still practice.
Practising clinicians, principal investigators, and translational scientists sit in our scientific advisory network, reviewing diligence in oncology, metabolic disease, cell & gene therapy, and AI-native drug discovery before we commit capital. Confidential, compensated, and structured — not a favor called in the week before an investment committee meeting.
Learn more → Collaborate: Scientific Advisory Network.
Access to capital beyond our own fund size.
Deal-by-deal co-investment access to our syndicate of institutional LPs, family offices, and strategic corporates — including a growing base of Gulf sovereign wealth relationships actively building healthcare and biotech allocations. When a portfolio company needs a growth round larger than our own reserve can carry alone, that syndicate is already warm.
Learn more → Collaborate: Strategic Co-Investment.
Built for a decade, not a fund cycle.
Three funds deployed, a fourth in formation, and continuity of thesis and team across all of them. We're not chasing whatever category is fashionable this quarter — the healthcare, drug discovery, HealthTech, MedTech, and AI-biotech mandate has held since Fund I, which means the relationships, the diligence playbooks, and the operating partner bench all compound rather than reset with each new vehicle.
Enablement, concretely.
Six specific ways this shows up for a portfolio company, in the order most founders encounter them.
Regulatory and cross-border navigation
Structuring cross-border operations, understanding which regulatory body actually governs a given trial or launch, and sequencing market entry across our six geographies so you're not learning India's CDSCO requirements or Kenya's Pharmacy and Poisons Board process by trial and error.
Customer and channel access
Direct introductions to hospital systems, pharmaceutical companies, payers, and distribution channels — the relationships that turn a validated product into a revenue line, not just a clinical result.
Clinical and commercial operating support
Hands-on partnership on pivotal trial design, regulatory strategy, and commercial roadmap — delivered by operating partners who have run exactly this kind of inflection point before, not generic startup advice ported over from a different industry.
Follow-on capital access
A warm syndicate of co-investors for growth rounds, built over multiple funds rather than assembled cold when a company needs to raise.
Industry relationships that shorten diligence cycles
Standing relationships with key opinion leaders, CROs, manufacturers, and regulators — the kind of network that turns a six-month partner search into a six-week one.
Mentorship from people who've done the exit
Direct pairing with operating partners who have built and sold healthcare companies — not a mentorship program with a syllabus, a relationship with someone who has specifically been where you're trying to go.